Rosemary Wells, LPC in Boulder, UT - Counselor

Rosemary Wells, LPC is a Counselor - Professional based in Boulder, Utah. Rosemary Wells is licensed to practice in Idaho (license number LCPC6832) and her current practice location is 4685 Navajo St., Boulder, Utah. She can be reached at her office (for appointments etc.) via phone at (208) 815-0042.

NPI number for Rosemary Wells is 1689005845 and her current mailing address is Po Box 1480, Boulder, Utah. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1689005845.

Contact Information

	Rosemary Wells, LPC
	4685 Navajo St., Boulder, UT 84716
	(208) 815-0042
	Not Available

Healthcare Provider's Profile

Full Name	Rosemary Wells
Gender	Female
Speciality	Counselor - Professional
Location	4685 Navajo St., Boulder, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1689005845
Provider Enumeration Date: 12/12/2013
Last Update Date: 01/11/2024

Medical Identifiers

Medical identifiers for Rosemary Wells such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1689005845	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YP2500X	Counselor - Professional	LCPC6832 (Idaho)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Rosemary Wells is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Rosemary Wells, LPC Po Box 1480, Boulder, UT 84716-1480 Ph: (208) 815-0042	Rosemary Wells, LPC 4685 Navajo St., Boulder, UT 84716 Ph: (208) 815-0042

News Archive

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

BDNF could someday play significant role in prevention of high blood pressure: Study

Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have discovered that nitric oxide is a powerful regulator of a molecule that plays a critical role in the development and function of the nervous system. The finding could someday play a significant role in the prevention and treatment of high blood pressure, which affects about one in three adults in the United States.

American HomePatient signs eighth forbearance agreement with NexBank, SSB

American HomePatient, Inc., one of the nation's largest home health care providers, today announced that it has entered into an eighth forbearance agreement with NexBank, SSB, the agent for its senior debt (the "Agent"), and the holders in interest of a majority of the senior debt (the "Forbearance Holders").

Myopia on the rise across Europe, new study finds

Myopia or short-sightedness is becoming more common across Europe, according to a new study led by King's College London. The meta-analysis of findings from 15 studies by the European Eye Epidemiology Consortium found that around a quarter of the European population is short-sighted but it is nearly twice as common in younger people, with almost half (47 per cent) of the group aged between 25 and 29 years affected.

Rosemary Wells, LPC - Counselor in Boulder, UT